These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23832064)

  • 21. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
    Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
    Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The in-vitro anticoagulant effect of rivaroxaban in neonates.
    Attard C; Monagle P; Kubitza D; Ignjatovic V
    Blood Coagul Fibrinolysis; 2014 Apr; 25(3):237-40. PubMed ID: 24418940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.
    Sadeghi N; Kahn D; Jeske W; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2013; 19(6):589-99. PubMed ID: 23463187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of methods to determine rivaroxaban anti-factor Xa activity.
    Rathbun S; Tafur A; Grant R; Esmon N; Mauer K; Marlar RA
    Thromb Res; 2015 Feb; 135(2):394-7. PubMed ID: 25476589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
    Grottke O; van Ryn J; Spronk HM; Rossaint R
    Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.
    Chojnowski K; Górski T; Robak M; Treliński J
    Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
    Lee FM; Chan AK; Lau KK; Chan HH
    Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
    Molenaar PJ; Dinkelaar J; Leyte A
    Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
    Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
    Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
    Dinkelaar J; Molenaar PJ; Ninivaggi M; de Laat B; Brinkman HJ; Leyte A
    J Thromb Haemost; 2013 Jun; 11(6):1111-8. PubMed ID: 23578206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
    Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
    PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
    Tanaka KA; Szlam F; Dickneite G; Levy JH
    Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of laboratory coagulation tests and clotting factor levels on Rotation Thromboelastometry (ROTEM(R)) during major surgery with hemorrhage.
    Theusinger OM; Schröder CM; Eismon J; Emmert MY; Seifert B; Spahn DR; Baulig W
    Anesth Analg; 2013 Aug; 117(2):314-21. PubMed ID: 23780419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
    Kubitza D; Becka M; Mück W; Krätzschmar J
    Br J Clin Pharmacol; 2014 Aug; 78(2):353-63. PubMed ID: 24528331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
    Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
    J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
    Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
    Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.